Ucsf Memory And Aging Center

San Francisco, California 95158

1 studies enrolling now · 22 studies all time

What they study most

Alzheimer Disease, Alzheimer's Disease, Alzheimers Disease, Anxiety, Awe, Cognitive Decline, Cognitive Impairment, Compassion, Corticobasal Degeneration Syndrome, Dementia, Early Alzheimer's Disease, Frontotemporal Lobar Degeneration With Tau Inclusions

Studies at this site

• A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — Recruiting now
• Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology — Running, not enrolling
• A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease — Running, not enrolling
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) — Running, not enrolling
• Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey — Status unconfirmed
• A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 — Stopped early
• Study of BHV-3241 in Participants With Multiple System Atrophy — Completed
• Therapeutic Antibodies Against Prion Diseases From PRNP Mutation Carriers — Completed
• Impact of Photobiomodulation (PBM) on Biomarkers of Alzheimer's Disease — Completed
• Improving Mental Health and Well-Being Via Awe Walks — Completed
• 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease — Stopped early
• Mindfulness Based Stress Reduction for Older Adults With HIV Associated Neurocognitive Disorders — Completed
• A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD). — Stopped early
• A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) — Stopped early
• An Open-Label Crenezumab Study in Participants With Alzheimer's Disease — Stopped early
• A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease — Completed
• BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES — Stopped early
• A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease — Completed
• Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations — Completed
• Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation — Status unconfirmed
• Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease — Completed
• Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy — Completed